| 4,872 | 72 | 62 |
| 下载次数 | 被引频次 | 阅读次数 |
TLR4/MyD88/NF-κB信号通路主要包括toll样受体4(toll-like receptor 4,TLR4)、髓样分化因子88(myeloid differentiation factor 88,MyD88)和核因子κB(nuclear factor-κB,NF-κB),在免疫及炎症机制中发挥作用。现已证实该通路的激活可导致多种疾病,其中肠易激综合征(IBS)在消化系统中发病率逐年升高,在分子机制的研究中,TLR4/MyD88/NF-κB信号通路在IBS尤其是IBS-D肠道低度炎症中的作用逐渐被人们重视。本文将对TLR4/MyD88/NF-κB信号通路的研究进展作一概述。
Abstract：The TLR4/MyD88/NF-κB signaling pathway is mainly composed of toll-like receptor 4(TLR4), myeloid differentiation factor 88(MyD88) and nuclear factor-κB(NF-κB) and it plays an important role in immune inflammation. It has been confirmed that the activation of this pathway leads to many diseases, of which the incidence of irritable bowel synclrome(IBS) in the digestive system is increasing year by year. In the molecular mechanism study, the role of the TLR4/MyD88/NF-κB signaling pathway in intestinal low inflammation has become more and more important. In this paper, it will describe the research progress of TLR4/MyD88/NF-κB signaling pathway.
[1] BUCKLEY M M,O’MAHONY S M,O’MALLEY D.Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome [J].World J Gastroenterol,2014,20(27):8846-8858.DOI:10.3748/wjg.v20.i27.8846.
[2] OSTERTAG D,BUHNER S,MICHEL K,et al.Reduced responses of submucous neurons from irritable bowel syndrome patients to a Cocktail Containing Histamine,Serotonin,TNFα,and Tryptase (IBS-Cocktail) [J].Front Neurosci,2015,9:465.DOI:10.3389/fnins.2015.00465.
[3] HALMOS E P,POWER V A,SHEPHERD S J,et al.A diet low in FODMAPs reduces symptoms of irritable bowel syndrome [J].Gastroenterology,2014,146(1):67-75.DOI:10.1053/j.gastro.2013.09.046.
[4] TAKEDA K,AKIRA S.Toll-like receptors [J].Curr Protoc Immunol,2015,109:14.12.1-10.DOI:10.1002/0471142735.im1412s109.
[5] CAI X,CHIU Y H,CHEN Z J.The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling [J].Mol Cell,2014,54(2):289-296.DOI:10.1016/j.molcel.2014.03.040.
[6] HAJJAR A M,ERNST R K,YI J,et al.Expression level of human TLR4 rather than sequence is the key determinant of LPS responsiveness [J].PLoS One,2017,12(10):e0186308.DOI:10.1371/journal.pone.0186308.
[7] SATOH T,AKIRA S.Toll-like receptor signaling and its inducible proteins [J].Microbiol Spectr,2016,4(6):1128.DOI:10.1128/microbiolspec.MCHD-0040-2016.
[8] AKIRA S,TAKEDA K.Toll-like receptor signalling [J].Nat Rev Immunol,2004,4(7):499-511.DOI:10.1038/nri1391.
[9] ZHANG D,ZHANG G,HAYDEN M S,et al.A toll-like receptor that prevents infection by uropathogenic bacteria [J].Science,2004,303(5663):1522-1526.DOI:10.1126/science.1094351.
[10] SHI M,ZHANG Y,LIU L,et al.MAP1S protein regulates the phagocytosis of bacteria and Toll-like receptor (TLR) signaling [J].J Biol Chem,2016,291(3):1243-1250.DOI:10.1074/jbc.M115.687376.
[11] LI T T,OGINO S,QIAN Z R.Toll-like receptor signaling in colorectal cancer:carcinogenesis to cancer therapy [J].World J Gastroenterol,2014,20(47):17699-17708.DOI:10.3748/wjg.v20.i47.17699.
[12] UNO K,KATO K,SHIMOSEGAWA T.Novel role of toll-like receptors in Helicobacter pylori - induced gastric malignancy [J].World J Gastroenterol,2014,20(18):5244-5251.DOI:10.3748/wjg.v20.i18.5244.
[13] IOANNOU S,VOULGARELIS M.Toll-like receptors,tissue injury,and tumourigenesis [J].Mediators Inflamm,2010,2010:581837.DOI:10.1155/2010/581837.
[14] JEZIERSKA A,KOLOSOVA I A,VERIN A D.Toll like receptors signaling pathways as a target for therapeutic interventions [J].Curr Signal Transduct Ther,2011,6(3):428-440.DOI:10.2174/157436211797483930.
[15] LEE J Y,LEE B H,LEE J Y.Gambogic acid disrupts Toll-like receptor4 activation by blocking lipopolysaccharides binding to myeloid differentiation factor 2 [J].Toxicol Res,2015,31(1):11-16.DOI:10.5487/TR.2015.31.1.011.
[16] MEDVEDEV A E.Toll-like receptor polymorphisms,inflammatory and infectious diseases,allergies,and cancer [J].J Interferon Cytokine Res,2013,33(9):467-484.DOI:10.1089/jir.2012.0140.
[17] LI J,YANG F,WEI F,et al.The role of toll-like receptor 4 in tumor microenvironment [J].Oncotarget,2017,8(39):66656-66667.DOI:10.18632/oncotarget.19105.
[18] PRADERE J P,DAPITO D H,SCHWABE R F.The Yin and Yang of toll-like receptors in cancer [J].Oncogene,2014,33(27):3485-3495.DOI:10.1038/onc.2013.302.
[19] EARL T M,NICOUD I B,PIERCE J M,et al.Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis [J] .Ann Surq Oncol,2009,16 (4):1043-1050.DOI:10.1245/s10434-009-0325-8.
[20] SEPEHRI Z,KIANI Z,KOHAN F,et al.Toll like receptor 4 and hepatocellular carcinoma:a systematic review [J].Life Sci,2017,179:80-87.DOI:10.1016/j.lfs.2017.04.025.
[21] CHEN J,LI J,YIU J,et al.TRIF-dependent toll-like receptor signaling suppresses Scd1 transcription in hepatocytes and prevents diet-induced hepatic steatosis [J].Sci Signal,2017,10(491):pii:eaal3336.DOI:10.1126/scisignal.aal3336.
[22] ROH Y S,SEKI E.Toll-like receptors in alcoholic liver disease,non-alcoholic steatohepatitis and carcinogenesis [J].J Gastroenterol Hepatol,2013,Suppl 1:38-42.DOI:10.1111/jgh.12019.
[23] GU J,SUN R,SHEN S,et al.The influence of TLR4 agonist lipopolysaccharides on hepatocellular carcinoma cells and the feasibility of its application in treating liver cancer [J].Onco Targets Ther,2015,8:2215-2225.DOI:10.2147/OTT.S86536.
[24] LU Y,XU J,CHEN S,et al.Lipopolysaccharide promotes angiogenesis in mice model of HCC by stimulating hepatic stellate cell activation via TLR4 pathway [J].Acta Biochim Biophys Sin (Shanghai),2017,49(11):1029-1034.DOI:10.1093/abbs/gmx100.
[25] ZHI-FENG W,LE-YUAN Z,XIAO-HUI Z,et al.TLR4-dependent immune response promotes radiation-induced liver disease by changing the liver tissue interstitial microenvironment during liver cancer radiotherapy [J].Radiat Res,2014,182(6):674-682.DOI:10.1667/RR13630.1.
[26] LIU R,LUO F,LIU X,et al.Biological response modifier in cancer immunotherapy [J].Adv Exp Med Biol,2016,909:69-138.DOI:10.1007/978-94-017-7555-7_2.
[27] STINTZING S.Personalized treatment for colorectal carcinomas [J].Dtsch Med Wochenschr,2017,142(22):1652-1659.DOI:10.1055/s-0043-108467.
[28] SO E Y,OUCHI T.The application of Toll like receptors for cancer therapy [J].Int J Biol Sci,2010,6(7):675-681.
[29] YE K,WU Y,SUN Y,et al.TLR4 siRNA inhibits proliferation and invasion in colorectal cancer cells by downregulating ACAT1 expression [J].Life Sci,2016,155:133-139.DOI:10.1016/j.lfs.2016.05.012.
[30] SHENG W Y,YONG Z,YUN Z,et al.Toll-like receptor 4 gene polymorphisms and susceptibility to colorectal cancer:a meta-analysis and review [J].Arch Med Sci,2015,11(4):699-707.DOI:10.5114/aoms.2015.53288.
[31] KUO W T,LEE T C,YANG H Y,et al.LPS receptor subunits have antagonistic roles in epithelial apoptosis and colonic carcinogenesis [J].Cell Death Differ,2015,22(10):1590-1604.DOI:10.1038/cdd.2014.240.
[32] YE K,CHEN Q W,SUN Y F,et al.Loss of BMI-1 dampens migration and EMT of colorectal cancer in inflammatory microenvironment through TLR4/MD-2/MyD88-mediated NF-κB signaling [J].J Cell Biochem,2018,119(2):1922-1930.DOI:10.1002/jcb.26353.
[33] LACY B E,PATEL N K.Rome criteria and a diagnostic approach to irritable bowel syndrome [J].J Clin Med,2017,6(11):E99.DOI:10.3390/jcm6110099.
[34] SAYUK G S,GYAWALI C P.Irritable bowel syndrome:modern concepts and management options [J].Am J Med,2015,128(8):817-827.DOI:10.1016/j.amjmed.2015.01.036.
[35] CANAVAN C,WEST J,CARD T.The economic impact of the irritable bowel syndrome [J].Aliment Pharmacol Ther,2014,40(9):1023-34.DOI:10.1111/apt.12938.
[36] LOVELL R M,FORD A C.Global prevalence of and risk factors for irritable bowel syndrome:a meta-analysis [J].Clin Gastroenterol Hepatol,2012,10(7):712-721.DOI:10.1016/j.cgh.2012.02.029.
[37] ZHANG F,XIANG W,LI C Y,et al.Economic burden of?irritable bowel syndrome in China [J].World J Gastroenterol,2016,22(47):10450-10460.DOI:10.3748/wjg.v22.i47.10450.
[38] SU A M,SHIH W,PRESSON A P,et al.Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern [J].Neuro gastroenterol Motil,2014,26(1):36-45.DOI:10.1111/nmo.12220.
[39] OSHIMA T,MIWA H.Irritable bowel syndrome:What physicians should know?[J].J Neurosci Rural Pract,2015,6(4):467-468.DOI:10.4103/0976-3147.168422.
[40] LEE K N,LEE O Y.Intestinal microbiota in pathophysiology and management of irritable bowel syndrome [J].World J Gastroenterol,2014,20(27):8886-8897.DOI:10.3748/wjg.v20.i27.8886.
[41] RINGEL Y,MAHARSHAK N.Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome [J].Am J Physiol Gastrointest Liver Physiol,2013,305(8):529-541.DOI:10.1152/ajpgi.00207.2012.
[42] BALEMANS D,MONDELAERS S U,CIBERT-GOTON V,et al.Evidence for long-term sensitization of the bowel in patients with post-infectious-IBS [J].Sci Rep,2017,7(1):13606.DOI:10.1038/s41598-017-12618-7.
[43] LEE Y Y,ANNAMALAI C,RAO S S C.Post-infectious irritable bowel syndrome [J].Curr Gastroenterol Rep,2017,19(11):56.DOI:10.1007/s11894-017-0595-4.
[44] 庄李磊,胡团敏.炎症免疫与肠易激综合征关系的研究进展[J].世界华人消化杂志,2013,21(20):1950-1954.ZHUANG L L,HU T M.Advances in understanding the relationship between inflammatory immune response and irritable bowel syndrome [J].World Chinese Journal of Digestology,2013,21(20):1950-1954.
[45] LIU S,HAGIWARA S I,BHARGAVA A.Early-life adversity,epigenetics,and visceral hypersensitivity [J].Neurogastroenterol Motil,2017,29(9).DOI:10.1111/nmo.13170.
[46] CEULEERS H,VAN S H,HANNING N,et al.Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome:the role of proteases [J].World J Gastroenterol,2016,22(47):10275-10286.DOI:10.3748/wjg.v22.i47.10275.
[47] YUAN B,TANG W H,LU LJ,et al.TLR4 upregulates CBS expression through NF-κB activation in a rat model of irritable bowel syndrome with chronic visceral hypersensitivity [J].World J Gastroenterol,2015,21(28):8615-8628.DOI:10.3748/wjg.v21.i28.8615.
[48] CHEN Z Y,ZHANG X W,YU L,et al.Spinal toll-like receptor 4-mediated signalling pathway contributes to visceral hypersensitivity induced by neonatal colonic irritation in rats [J].Eur J Pain,2015,19(2):176-186.DOI:10.1002/ejp.534.
[49] ?RFI E,SZEBENI J.The immune system of the gut and potential adverse effects of oral nanocarriers on its function [J].Adv Drug Deliv Rev,2016,106 (Pt B):402-409.DOI:10.1016/j.addr.2016.09.009.
[50] WOUTERS M M,VICARIO M,SANTOS J.The role of mast cells in functional GI disorders [J].Gut,2016,65(1):155-168.DOI:10.1136/gutjnl-2015-309151.
[51] CLARKE G,MCKERNAN D P,GASZNER G,et al.A distinct profile of tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor activation in irritable bowel syndrome [J].Front Pharmacol,2012,3:90.DOI:10.3389/fphar.2012.00090.
[52] CHEN B,ZHU S,DU L,et al.Reduced interstitial cells of Cajal and increased intraepithelial lymphocytes are associated with development of small intestinal bacterial overgrowth in post-infectious IBS mouse model [J].Scand J Gastroenterol,2017,52(10):1065-1071.DOI:10.1080/00365521.2017.1342141.
[53] MCKERNAN D P,GASZNER G,QUIGLEY E M,et al.Altered peripheral toll-like receptor responses in the irritable bowel syndrome [J].Aliment Pharmacol Ther,2011,33(9):1045-1052.DOI:10.1111/j.1365-2036.2011.04624.x.
[54] IBARRA C,HERRERA V,PéREZ A E,et al.Parasitosis and irritable bowel syndrome [J].Rev Chilena Infectol,2016,33(3):268-274.DOI:10.4067/S0716-10182016000300003.
[55] COMPARE D,ROCCO A,COCCOLI P,et al.Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response:an ex-vivo organ culture model of post-infectious irritable bowel syndrome [J].BMC Gastroenterol,2017,17(1):53.DOI:10.1186/s12876-017-0605-x.
[56] RETI K L,TYMENSEN L D,DAVIS S P,et al.Campylobacter jejuni increases flagellar expression and adhesion of noninvasive Escherichia coli:effects on enterocytic Toll-like receptor 4 and CXCL-8 expression [J].Infect Immun,2015,83(12):4571-4581.DOI:10.1128/IAI.00970-15.
[57] BEATTY J K,AKIERMAN S V,MOTTA J P,et al.Giardia duodenalis induces pathogenic dysbiosis of human intestinal microbiota biofilms [J].Int J Parasitol,2017,47(6):311-326.DOI:10.1016/j.ijpara.2016.11.010.
[58] HYLAND N P,QUIGLEY E M,BRINT E.Microbiota-host interactions in irritable bowel syndrome:epithelial barrier,immune regulation and brain-gut interactions [J].World J Gastroenterol,2014,20(27):8859-8866.DOI:10.3748/wjg.v20.i27.8859.
[59] DONG L N,WANG J P,LIU P,et al.Faecal and mucosal microbiota in patients with functional gastrointestinal disorders:correlation with toll-like receptor 2/toll-like receptor 4 expression [J].World J Gastroenterol,2017,23(36):6665-6673.DOI:10.3748/wjg.v23.i36.6665.
[60] AGUILERA M,CERDà-CUéLLAR M,MARTíNEZ V.Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice [J].Gut Microbes,2015,6(1):10-23.DOI:10.4161/19490976.2014.990790.
基本信息:
DOI：
中图分类号:R363
引用信息:
[1]鲍璐璐,崔立红.TLR4/MyD88/NF-κB信号通路的研究进展[J].胃肠病学和肝病学杂志,2019,28(05):568-572.
基金信息:
国家自然科学基金面上项目(81670494)